Market Trends of Global Sirolimus Industry
This section covers the major market trends shaping the Sirolimus Market according to our research experts:
Organ Transplant Rejection Segment is Expected to Hold a Major Market Share in the Sirolimus Market
Organ transplantation is a medical procedure used to replace a damaged or missing organ by removing it from the donor and placing it in the body of the recipient. To lower the body's ability to reject a transplanted organ immunosuppressants or anti-rejection drugs such as sirolimus are used.
According to the United States Department of Health and Human Services and Health Resources and Services Administration, nationwide, 13,861 persons donated their organs after passing away in 2021, setting a record for deceased donation for the eleventh year in a row and up 10.1% over the previous year i.e. 2020. The weekly total of deceased donors went over 300 for the first time in May 2021; the 300 donor mark was also exceeded twice more in June 2021. As the United States is one of the major countries for organ transplants, the market for sirolimus is expected to witness strong growth in the country.
Additionally, as per the data published by the Council of Europe in September 2021, there were over 16,000 kidney transplants done in Europe in the year 2020 whereas as of the year 2021, around 1,150 people were waiting for heart transplantation in Europe. Hence, increasing transplantation rates, the occurrence of lifestyle-related diseases, and technological advancements in organ transplantation are the key driving factors in the organ transplant rejection segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global sirolimus market due to the high volume of organ transplants, rising incidence of chronic diseases, and presence of favorable reimbursement policies in this region. According to the Disease Control and Prevention (CDC) 2021 data, the most commonly transplanted organs in the United States are kidney, liver, heart, lungs, pancreas, and intestine. On average every day, there are about 75,000 people on the active waiting list for organ transplantation. Furthermore, technological advancements in organ transplantation, increasing healthcare spending, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
Preliminary figures from United Network for Organ Sharing (UNOS), which acts as the Organ Procurement and Transplantation Network under federal contract, show that 41,354 organ transplants were carried out in the United States in 2021, up 5.9 percent from 2020 and for the first time the annual total exceeded 40,000.
Hence, from the above-mentioned factors, it is observed that North America is expected to witness a strong share in the sirolimus market.
